MedTrace Logo

Amiloride in Nephrotic Syndrome

NCT05079789 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-01-14

Study results available
· View outcomes & findings →

Summary

The AMILOR study compares treatment of edema in nephrotic syndrome with Amiloride vs. Furosemide.

Conditions

  • Nephrotic Syndrome
  • Edema
  • Sodium Retention

Interventions

DRUG

Amiloride

Treatment with amiloride, start dose 5 mg

DRUG

Furosemide

Treatment with furosemide, start dose 40 mg

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Ferruh Artunc, Prof., MD · University Hospital Tuebingen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-08
Primary Completion
2022-11-05
Completion
2022-11-20

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05079789 on ClinicalTrials.gov